Pidnarulex (CX-5461)

ArtNr	S2684-5
Hersteller	Selleckchem
CAS-Nr.	1138549-36-6
Menge	5 mg
Quantity options	10 mg 1 g 10 g 200 mg 5 mg 50 mg 5 g
Kategorie	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Skin Cancer Bladder Cancer Colorectal Cancer Breast Cancer Testicular & Prostate Cancer
Typ	Inhibitors
Specific against	other
Smiles	CC1=CN=C(C=N1)CNC(=O)C2=C3N(C4=CC=CC=C4S3)C5=C(C2=O)C=CC(=N5)N6CCCN(CC6)C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Pol I,HCT-116,A375,MIA PaCa-2,DNA/RNA Synthesis
Similar products	CX-5461
Lieferbar
Storage Conditions	2 years -80 in solvent
Molecular Weight	513, 61
Administration	CX-5461 is administered orally once daily or every 3 days.
Animal Models	5, 106 MIA Paca-2 and A375 cancer cells are subcutaneously inoculated in the right flank of 5- to 6- week-old female athymic mice
Cell lines	panel of cancer and normal cell lines
Concentrations	0-2 uM
Dosages	50 mg/kg
Formulation	CX-5461 is dissolved in 50 mM NaH2PO4 (pH 4.5).
IC50	142 nM, 142 nM, 142 nM, 142 nM, 142 nM, 142 nM
In vitro	CX-5461 is found to selectively inhibit rRNA synthesis (Pol I IC50=142 nM, Pol II IC50 > 25 uM, selectivity ca.200-fold) in the HCT-116 cells. Selective inhibition of rRNA synthesis by CX-5461 is confirmed in two other human solid tumor cell lines, melanoma A375 (Pol I IC50 = 113 nM, Pol II IC50 > 25 uM) and pancreatic carcinoma MIA PaCa-2 (Pol I IC50=54 nM, Pol II IC50 ca.25 mM). CX-5461 possesses 250- to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation. CX-5461 exhibits broad antiproliferative potency in a panel of cancer cell lines in human cancer cell lines, but has minimal effect on viability of nontransformed human cells. The median EC50 across all tested cell lines is 147 nM, yet all normal cell lines have EC50 values of approximately 5, 000 nM. Evaluation of the antiproliferative dose response for HCT-116, A375, and MIA PaCa-2 cell lines yield EC50 values of 167, 58, and 74 nM. CX-5461 induces autophagy and senescence in solid tumor cancer cells, rather than apoptosis, through a p53-independent process. [1]
In vivo	CX-5461 is orally bioavailable and demonstrates in vivo antitumor activity against human solid tumors in murine xenograft models. CX-5461 demonstrates significant MIA PaCa-2 TGI with TGI equal to 69% on day 31, comparable to that of gemcitabine (63% TGI). Gemcitabine is a positive control which is administered intraperitoneally once every 3 days at 120 mg/kg. Likewise, CX- 5461 demonstrates significant A375 TGI with TGI equal to 79% on day 32. [1]
Incubation Time	96 hours
Kinase Assay	Pol I and Pol II Transcription Assay, Two short-lived RNA transcripts (half-lives ca.20â€“30 minutes), one produced by Pol I and another by Pol II, are quantitated by qRT-PCR as a measure of CX-5461-related effects on transcription. The 45S pre-rRNA served as the Pol I transcript and the mRNA for the protooncogene c-myc served as the comparator Pol II transcript. Both Pol I and Pol II transcription are known to be affected by general cellular stress. To minimize the potential effects of such stress, cells are exposed to test agents for only a short period of time (2 hours). This is sufficient time for these transcripts to be reduced by greater than 90% if CX-5461 affects their synthesis.
Method	Cells are plated on 96-well plates and treated the next day with dose response of CX-5461 for 96 hours. Cell viability is determined using Alamar Blue and CyQUANT assays
Solubility (25C)	DMSO <1 mg/mL, Water <1 mg/mL, Ethanol <1 mg/mL
Information	Pidnarulex (CX-5461) is an inhibitor of rRNA synthesis, selectively inhibits Pol I-driven transcription of rRNA with IC50 of 142 nM in HCT-116, A375, and MIA PaCa-2 cells, has no effect on Pol II, and possesses 250- to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation.
Chemical Name	5H-Benzothiazolo[3, 2-a][1, 8]naphthyridine-6-carboxamide, 2-(hexahydro-4-methyl-1H-1, 4-diazepin-1-yl)-N-[(5-methyl-2-pyrazinyl)methyl]-5-oxo-

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

S2684-5-datasheet.pdf

S2684-5-safety-datasheet.pdf